Anemia drug by Takeda and Affymax is submitted for FDA OK

05/31/2011 | Forbes · Pharmaceutical Business Review Online

Affymax and Takeda Pharmaceutical are seeking FDA approval of peginesatide, a drug candidate for anemia in kidney dialysis patients. The once-monthly drug, formerly called Hematide, appears as safe and effective as epoetin alfa or epoetin beta in stabilizing hemoglobin level, according to results of two Phase III trials.

View Full Article in:

Forbes · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ